NKGN — Nkgen Biotech Balance Sheet
0.000.00%
- $5.71m
- $36.01m
Annual balance sheet for Nkgen Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Cash and Equivalents | |||
Cash and Short Term Investments | 0.351 | 0.117 | 0.026 |
Net Total Accounts Receivable | |||
Net Total Receivables | 0.067 | 0.096 | 0.026 |
Prepaid Expenses | |||
Total Other Current Assets | |||
Total Current Assets | 0.612 | 0.35 | 1.93 |
Gross Property, Plant And Equipment | |||
Accumulated Depreciation | |||
Net Property, Plant And Equipment | 17.4 | 15.9 | 14.5 |
Net Intangible Assets | |||
Total Assets | 18.1 | 16.3 | 16.5 |
Accounts Payable | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Current Portion of Long Term Debt / Capital Leases | |||
Total Other Current Liabilities | |||
Total Current Liabilities | 55.7 | 14.7 | 39.5 |
Long Term Debt | |||
Total Long Term Debt | |||
Total Debt | |||
Deferred Income Tax | |||
Total Other Liabilities | |||
Total Liabilities | 56.1 | 14.8 | 75.2 |
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Other Equity | |||
Total Equity | -38.1 | 1.56 | -58.7 |
Total Liabilities & Shareholders' Equity | 18.1 | 16.3 | 16.5 |
Total Common Shares Outstanding |